GNFTY

Genfit S.A.

OTC · Biological Products, (No Diagnostic Substances) · Inc. I0 · CIK 0001757064
Vol
Inst. Holders2 funds
Inst. Value$97.2K
Inst. Activity0 buys / 1 sells
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. I0·CIK 0001757064

Recent Activity

Inst.
MORGAN STANLEY — EXIT
0 shares ($0.00)
Inst.
MORGAN STANLEY — TRIM
20,120 shares ($76.5K)

Price Targets

Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$9.16 (Sep 2025)
Current $8.95 Low $6.97 Median $7.95 High $12.56 3 analysts
$6.97 $12.56

Analyst Ratings

Historical distribution92% buy · 12 analysts · last covering-analyst action Sep 2025
7Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Sep 24, 2025 HC Wainwright & Co. MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Next FY $-0.22 $-0.53 — $0.09 -19% YoY 2
Current FY $-0.18 $-0.23 — $-0.14 -717% YoY 2

Top Institutional Holders

FundValueMove
MORGAN STANLEY$76.5KEXIT
UBS Group AG$20.7KADD
2 institutional holders with $97.2K total value (25,569 shares) as of 2025-Q3. Top holders: MORGAN, UBS.

Top Institutional Holders — 2025-Q3

#FundSharesValue% of TrackedLast Move
1MORGAN STANLEY20,120$76.5K78.7%EXIT -100.0%
2UBS Group AG5,449$20.7K21.3%ADD +33.5%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
MORGAN STANLEYEXIT20,1200-100.0%$0.002025-Q4
MORGAN STANLEYTRIM27,42020,120-26.6%$76.5K2025-Q3
UBS Group AGADD4,0815,449+33.5%$20.7K2025-Q3
UBS Group AGADD3,1184,081+30.9%$15.2K2025-Q2
BANK OF AMERICA CORP /DE/NEAR_EXIT171-94.1%$4.002025-Q2
MORGAN STANLEYTRIM34,72025,520-26.5%$87.3K2025-Q1
CITADEL ADVISORS LLCNEW12,331$44.3K2025-Q1
MORGAN STANLEYADD25,02034,720+38.8%$129.0K2024-Q4
UBS Group AGNEW3,048$11.3K2024-Q4

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Sep 2025): 92% buy across 12 analysts — 7 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$9.16 mean target (Sep 2025)
$6.97 Low $12.56 High
MetricValue
Current Price$8.95
Target Low$6.97
Target Mean$9.16
Target Median$7.95
Target High$12.56
# Analysts3
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Next Q
$0.00 $0.00 $0.00 $0.0B
Next FY
2026-12-31
$-0.22 $-0.53 $0.09 -18.9% +0.0% 2↑ 0↓ $0.1B 10.3% 2
Current Q
$0.00 $0.00 $0.00 $0.0B
Current FY
2025-12-31
$-0.18 $-0.23 $-0.14 -716.7% +0.0% 0↑ 1↓ $0.1B -2.4% 2
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Sep 24, 2025 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20267410092%
May 1, 20267410092%
Apr 1, 20267410092%
Mar 1, 20267410092%
Feb 1, 20267410092%
Jan 1, 20267410092%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.